Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:COLL
  • CUSIP: N/A
  • Web: www.collegiumpharma.com
Capitalization:
  • Market Cap: $304.83 million
  • Outstanding Shares: 29,566,000
Average Prices:
  • 50 Day Moving Avg: $10.41
  • 200 Day Moving Avg: $10.41
  • 52 Week Range: $9.68 - $20.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.48
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.44 million
  • Price / Sales: 40.97
  • Book Value: $3.23 per share
  • Price / Book: 3.19
Profitability:
  • EBIDTA: ($97,950,000.00)
  • Net Margins: -1,319.39%
  • Return on Equity: -93.73%
  • Return on Assets: -74.81%
Debt:
  • Current Ratio: 4.22%
  • Quick Ratio: 4.17%
Misc:
  • Average Volume: 269,257 shs.
  • Beta: -0.12
  • Short Ratio: 20.34
 

Frequently Asked Questions for Collegium Pharmaceutical (NASDAQ:COLL)

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.09. The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. View Collegium Pharmaceutical's Earnings History.

When will Collegium Pharmaceutical make its next earnings announcement?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Collegium Pharmaceutical.

Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2017?

5 brokers have issued 12 month target prices for Collegium Pharmaceutical's stock. Their predictions range from $14.00 to $25.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $20.00 in the next year. View Analyst Ratings for Collegium Pharmaceutical.

Who are some of Collegium Pharmaceutical's key competitors?

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:

  • Michael Thomas Heffernan, Chairman of the Board, President, Chief Executive Officer
  • Paul Brannelly CPA, Chief Financial Officer, Executive Vice President
  • Joseph J. Ciaffoni, Chief Operating Officer, Executive Vice President
  • Douglas R. Carlson, Vice President - Corporate Development
  • Alison B Fleming, Vice President of Product Development
  • Ernest A. Kopecky Ph.D., Vice President - Clinical Development and Head of Neuroscience
  • Kevin OKeeffe, Vice President - Market Access and Trade
  • Steven Passik Ph.D., Vice President - Scientific Affairs, Education and Policy
  • Said Saim Ph.D., Vice President of Pharmaceutical Development
  • John Weet Ph.D., Vice President - Regulatory Affairs and Quality Assurance

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who owns Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (7.48%), Frazier Management LLC (6.38%), Sectoral Asset Management Inc (6.12%), TPG Group Holdings SBS Advisors Inc. (4.70%), Macquarie Group Ltd. (3.78%) and Vanguard Group Inc. (2.68%). Company insiders that own Collegium Pharmaceutical stock include John A Fallon and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.

Who sold Collegium Pharmaceutical stock? Who is selling Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Franklin Resources Inc., Vanguard Group Inc., NBW Capital LLC and ProShare Advisors LLC. View Insider Buying and Selling for Collegium Pharmaceutical.

Who bought Collegium Pharmaceutical stock? Who is buying Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Macquarie Group Ltd., Granite Investment Partners LLC, Northern Trust Corp, State Street Corp, Bank of New York Mellon Corp, Bradley Foster & Sargent Inc. CT and Teachers Advisors LLC. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.

How do I buy Collegium Pharmaceutical stock?

Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of Collegium Pharmaceutical stock can currently be purchased for approximately $10.31.


MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  225
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Collegium Pharmaceutical (NASDAQ:COLL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (93.99% upside)

Analysts' Ratings History for Collegium Pharmaceutical (NASDAQ:COLL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Jefferies Group LLCReiterated RatingBuy$15.00HighView Rating Details
9/11/2017HC WainwrightInitiated CoverageBuy -> Buy$21.00HighView Rating Details
9/8/2017Piper Jaffray CompaniesReiterated RatingBuy$14.00LowView Rating Details
6/12/2017Janney Montgomery ScottReiterated RatingBuy$25.00MediumView Rating Details
6/9/2017Needham & Company LLCReiterated RatingBuy$25.00LowView Rating Details
9/13/2016GabelliInitiated CoverageBuy$25.00N/AView Rating Details
2/19/2016William BlairInitiated CoverageOutperform$35.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)
Earnings by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Earnings History by Quarter for Collegium Pharmaceutical (NASDAQ COLL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.75)N/AView Earnings Details
8/9/2017Q2 2017($0.81)($0.72)$4.07 million$3.56 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.98)($0.79)$3.55 million$2.17 millionViewN/AView Earnings Details
3/9/2017Q4 2016($1.07)($1.02)$1.79 million$1.30 millionViewListenView Earnings Details
11/10/2016Q3 2016($1.09)($1.13)$1.00 million$0.41 millionViewListenView Earnings Details
8/10/2016Q2($0.76)($1.05)$0.16 millionViewListenView Earnings Details
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details
8/12/2015Q215($0.26)($0.45)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)
2017 EPS Consensus Estimate: ($3.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.89)($0.89)($0.89)
Q2 20172($0.81)($0.76)($0.79)
Q3 20172($0.81)($0.67)($0.74)
Q4 20172($1.00)($0.61)($0.81)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Ownership Percentage: 25.76%
Institutional Ownership Percentage: 83.04%
Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Paul BrannellyInsiderBuy10,000$9.18$91,800.00View SEC Filing  
8/12/2016John A FallonDirectorBuy2,375$10.59$25,151.25View SEC Filing  
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Collegium Pharmaceutical (NASDAQ:COLL)
Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
Source:
DateHeadline
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - September 22 at 12:38 AM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 20 at 9:24 AM
benzinga.com logoBenzinga's Top Upgrades, Downgrades For September 11, 2017 - Benzinga
www.benzinga.com - September 11 at 6:04 PM
americanbankingnews.com logoCollegium Pharmaceutical's (COLL) Buy Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - September 9 at 3:06 PM
globenewswire.com logoCollegium to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - September 6 at 5:23 PM
globenewswire.com logoCollegium Announces Scientific Presentations at PAINWeek 2017 Meeting - GlobeNewswire (press release)
globenewswire.com - September 5 at 11:57 PM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 26 at 9:26 AM
nasdaq.com logoBioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End - Nasdaq
www.nasdaq.com - August 24 at 10:39 PM
americanbankingnews.com logo$5.03 Million in Sales Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter
www.americanbankingnews.com - August 23 at 11:32 AM
finance.yahoo.com logoCollegium Pharmaceutical, Inc. – Value Analysis (NASDAQ:COLL) : August 17, 2017
finance.yahoo.com - August 16 at 10:51 PM
americanbankingnews.com logoZacks Investment Research Upgrades Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to "Hold"
www.americanbankingnews.com - August 14 at 10:34 PM
americanbankingnews.com logoFY2017 Earnings Estimate for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Issued By Gabelli
www.americanbankingnews.com - August 14 at 5:52 AM
americanbankingnews.com logoJefferies Group Weighs in on Collegium Pharmaceutical, Inc.'s Q3 2017 Earnings (COLL)
www.americanbankingnews.com - August 14 at 3:18 AM
americanbankingnews.com logoWilliam Blair Comments on Collegium Pharmaceutical, Inc.'s Q3 2017 Earnings (COLL)
www.americanbankingnews.com - August 14 at 3:18 AM
americanbankingnews.com logoFY2020 EPS Estimates for Collegium Pharmaceutical, Inc. Lifted by Gabelli (NASDAQ:COLL)
www.americanbankingnews.com - August 11 at 5:22 PM
finance.yahoo.com logoEdited Transcript of COLL earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 11:40 PM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - August 10 at 11:04 PM
globenewswire.com logoCollegium Reports Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - August 9 at 5:37 PM
finance.yahoo.com logoCollegium Reports Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:37 PM
finance.yahoo.com logoCollegium Pharmaceutical posts 2Q loss
finance.yahoo.com - August 9 at 5:37 PM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Downgraded by BidaskClub
www.americanbankingnews.com - August 6 at 12:54 PM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Expected to Announce Quarterly Sales of $4.07 Million
www.americanbankingnews.com - August 5 at 9:34 AM
finance.yahoo.com logoCollegium Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : COLL-US : August 4, 2017
finance.yahoo.com - August 4 at 5:37 PM
americanbankingnews.com logoFinancial Survey: Collegium Pharmaceutical (NASDAQ:COLL) and Akorn (AKRX)
www.americanbankingnews.com - August 4 at 2:26 PM
americanbankingnews.com logo-$0.81 EPS Expected for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) This Quarter
www.americanbankingnews.com - August 3 at 7:26 AM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 1 at 8:53 AM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Given a $14.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - July 26 at 11:59 PM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. Expected to Post Q2 2017 Earnings of ($0.76) Per Share (COLL)
www.americanbankingnews.com - July 20 at 8:12 AM
nasdaq.com logoNektar's NKTR-181 Positive in Human Abuse Potential Study - Nasdaq
www.nasdaq.com - July 19 at 6:33 PM
nasdaq.com logoCollegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update - Nasdaq
www.nasdaq.com - July 18 at 11:53 PM
globenewswire.com logoCollegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update - GlobeNewswire (press release)
globenewswire.com - July 18 at 6:52 PM
feeds.benzinga.com logoCollegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
feeds.benzinga.com - July 18 at 4:34 PM
americanbankingnews.com logoCollegium Pharmaceutical Inc (COLL) Expected to Announce Quarterly Sales of $4.33 Million
www.americanbankingnews.com - July 13 at 10:48 AM
finance.yahoo.com logoEdited Transcript of COLL earnings conference call or presentation 10-May-17 8:30pm GMT
finance.yahoo.com - July 11 at 11:32 PM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - July 11 at 10:52 PM
americanbankingnews.com logo-$0.80 EPS Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter
www.americanbankingnews.com - July 11 at 8:24 PM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 7 at 10:52 AM
americanbankingnews.com logoFY2017 EPS Estimates for Collegium Pharmaceutical, Inc. Lowered by Analyst (COLL)
www.americanbankingnews.com - June 29 at 8:58 AM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - June 25 at 12:10 AM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Expected to Announce Quarterly Sales of $4.33 Million
www.americanbankingnews.com - June 17 at 8:00 AM
americanbankingnews.com logo-$0.80 Earnings Per Share Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter
www.americanbankingnews.com - June 15 at 8:44 PM
americanbankingnews.com logoAnalyzing Pacira Pharmaceuticals (PCRX) and Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - June 15 at 7:50 AM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 12 at 11:00 AM
americanbankingnews.com logoCollegium Pharmaceutical, Inc. (COLL) Stock Rating Reaffirmed by Janney Montgomery Scott
www.americanbankingnews.com - June 12 at 10:16 AM
fool.com logoWhy Endo's Bad News Sent Collegium Pharmaceutical Shares Soaring 10% - Motley Fool
www.fool.com - June 11 at 9:32 PM
globenewswire.com logoCollegium Announces Scientific Presentations at the 2017 ... - GlobeNewswire (press release)
globenewswire.com - June 10 at 9:38 PM
finance.yahoo.com logoCollegium's stock jumps on belief its opioid drug will get a boost from a rival's woes
finance.yahoo.com - June 10 at 3:07 AM
americanbankingnews.com logoNeedham & Company LLC Reaffirms Buy Rating for Collegium Pharmaceutical Inc (COLL)
www.americanbankingnews.com - June 9 at 10:48 PM
globenewswire.com logoCollegium Announces Scientific Presentations at the 2017 International Conference on Opioids - GlobeNewswire (press release)
globenewswire.com - June 9 at 5:00 PM

Social

Chart

Collegium Pharmaceutical (COLL) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff